Skip to main content

Table 3 Characteristics of the cytogenetic intermediate/high-risk group according to DNA methylation/hydroxymethylation levels

From: Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion

 

CLL patients with cytogenetic intermediate/high risk

 

5-mCyt low (n = 20)

5-mCyt high (n = 10)

Statistics (p)

5-hmCyt low (n = 23)

5-hmCyt high (n = 7)

Statistics (p)

Age at diagnosis, mean (±SD)

65.8 (± 10.3)

65.7 (± 8.0)

NS

69.6 (± 10.5)

71.1 (± 7.8)

NS

Age at study entry, mean (±SD)

70.3 (± 10.9)

69.1 (± 7.7)

NS

69.6 (± 10.9)

71.1 (± 7.8)

NS

Binet stage, No. of patients (%)

  

NS

  

NS

 A

8/20 (40%)

6/10 (60%)

 

9/23 (39.1%)

5/7 (71.4%)

 

 B/C

12/20 (60%)

4/10 (40%)

 

14/23 (60.9%)

2/7 (28.6%)

 

Lymphocytosis (Giga/L), mean (±SD)

93.5 (± 58.3)

27.9 (± 22.8)

0.0008

83.7 (± 60.0)

32.1 (± 26.5)

0.02

IGHV status, No. of patients (%)

  

NS

  

NS

Unmutated (≥ 98% homology)

4/13 (30.8%)

1/5 (20%)

 

5/15 (33.3%)

0/5 (0%)

 

Mutated (< 98% homology)

9/13 (69.2%)

4/5 (80%)

 

10/15 (66.7%)

5/5 (100%)

 

CD38 > 30%, No. of patients (%)

7/18 (38.9%)

4/10 (40%)

NS

7/21 (33.3%)

4/7 (57.1%)

NS

LDT from diagnosis, median (months)a

12

24

0.04

16.5

30

NS

PFS, median (months)a

40

46

NS

40

83

NS

TFS, median (months)a

72

> 120

NS

72

> 120

NS

  1. Abbreviations: 5-mCyt 5-methylcytosine, 5-hmCyt, 5-hydroxymethylcytosine, NS not significant, No. number, SD standard deviation, IGHV immunoglobulin heavy-chain variable region, LDT lymphocyte doubling time, PFS progression-free survival, TFS treatment-free survival, del deletion
  2. aKaplan–Meier survival analysis